Photocatalytic Dehydrogenative 6π‐Photocyclisation of Indole Derivatives via Successive Energy Transfer
摘要:
Herein, a successive energy transfer (sEnT) strategy to enable a dehydrogenative 6π‐photocyclisation, without the need for an external oxidant is reported, in which the energetically unfavourable dehydrogenation is driven by energy transfer. The valuable applicability of this method was demonstrated by the scaffold hopping of indole containing bioactive molecules, as well as by the succinct synthesis of naturally occurring tetracyclic furocarbazole alkaloids. Moreover, experimental and computational studies were conducted to elucidate the reaction mechanism.
Photocatalytic Dehydrogenative 6π‐Photocyclisation of Indole Derivatives via Successive Energy Transfer
摘要:
Herein, a successive energy transfer (sEnT) strategy to enable a dehydrogenative 6π‐photocyclisation, without the need for an external oxidant is reported, in which the energetically unfavourable dehydrogenation is driven by energy transfer. The valuable applicability of this method was demonstrated by the scaffold hopping of indole containing bioactive molecules, as well as by the succinct synthesis of naturally occurring tetracyclic furocarbazole alkaloids. Moreover, experimental and computational studies were conducted to elucidate the reaction mechanism.
Thermal 1,6-Electrocyclization Reactions of Acceptor-Substituted 2,3-Divinyl-1H-indoles Yielding Functionalized Carbazoles
作者:Ulf Pindur、Reinhard Adam
DOI:10.1002/hlca.19900730408
日期:1990.6.20
Three new synthetic procedures for and thermal 1,6-electrocyclizations of acceptor-substituted2,3-divinyl-1H-indoles leading to functionalizingcarbazoles are described. The scope and limitations as well as some mechanistic aspects of the methodologies are discussed. The key strategies employed include Pd(II)-catalyzed coupling and Wittig procedures.
PINDUR, ULF;ADAM, REINHARD, HELV. CHIM. ACTA, 73,(1990) N, C. 827-838
作者:PINDUR, ULF、ADAM, REINHARD
DOI:——
日期:——
INHIBITORS OF APOL1 AND METHODS OF USING SAME
申请人:Vertex Pharmacéuticals Incorporated
公开号:US20200377479A1
公开(公告)日:2020-12-03
The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomeulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).